Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $33,700.59 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 34,041 shares of the company’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $0.99, for a total value of $33,700.59. Following the transaction, the director directly owned 3,017,669 shares of the company’s stock, valued at approximately $2,987,492.31. This represents a 1.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Luke Evnin also recently made the following trade(s):

• On Tuesday, December 9th, Luke Evnin sold 44,570 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.01, for a total transaction of $45,015.70.
• On Friday, December 5th, Luke Evnin sold 16,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total value of $16,070.96.
• On Thursday, December 4th, Luke Evnin sold 53,416 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total value of $51,813.52.
• On Wednesday, December 3rd, Luke Evnin sold 36,726 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.87, for a total transaction of $31,951.62.
• On Tuesday, December 2nd, Luke Evnin sold 38,043 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total transaction of $33,858.27.
• On Monday, December 1st, Luke Evnin sold 39,096 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $36,750.24.
• On Friday, November 28th, Luke Evnin sold 13,014 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total transaction of $12,883.86.
• On Wednesday, November 26th, Luke Evnin sold 38,978 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total transaction of $38,198.44.
• On Tuesday, November 25th, Luke Evnin sold 27,297 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.92, for a total transaction of $25,113.24.
• On Monday, November 24th, Luke Evnin sold 56,992 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total value of $55,852.16.

Werewolf Therapeutics Stock Performance

Shares of HOWL stock traded up $0.01 during trading hours on Tuesday, reaching $1.01. 282,022 shares of the company’s stock were exchanged, compared to its average volume of 502,136. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87. Werewolf Therapeutics, Inc. has a 1 year low of $0.60 and a 1 year high of $2.38. The company has a market cap of $49.03 million, a P/E ratio of -0.62 and a beta of 0.74. The company’s 50 day moving average is $1.35 and its two-hundred day moving average is $1.33.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.03. Equities research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of large investors have recently bought and sold shares of the stock. MPM Asset Management LLC increased its holdings in shares of Werewolf Therapeutics by 0.6% during the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after buying an additional 25,688 shares during the last quarter. MPM Bioimpact LLC lifted its stake in shares of Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after purchasing an additional 20,799 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares during the period. Vanguard Group Inc. grew its holdings in shares of Werewolf Therapeutics by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares during the period. Finally, Jane Street Group LLC acquired a new stake in Werewolf Therapeutics during the 2nd quarter worth approximately $409,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Bank of America decreased their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. JMP Securities dropped their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. Finally, Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 21st. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $7.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.